Cargando…
Readthrough of nonsense mutations in Rett syndrome: evaluation of novel aminoglycosides and generation of a new mouse model
Thirty-five percent of patients with Rett syndrome carry nonsense mutations in the MECP2 gene. We have recently shown in transfected HeLa cells that readthrough of nonsense mutations in the MECP2 gene can be achieved by treatment with gentamicin and geneticin. This study was performed to test if rea...
Autores principales: | Brendel, Cornelia, Belakhov, Valery, Werner, Hauke, Wegener, Eike, Gärtner, Jutta, Nudelman, Igor, Baasov, Timor, Huppke, Peter |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Springer-Verlag
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3055984/ https://www.ncbi.nlm.nih.gov/pubmed/21120444 http://dx.doi.org/10.1007/s00109-010-0704-4 |
Ejemplares similares
-
Erratum to: Readthrough of nonsense mutations in Rett syndrome: evaluation of novel aminoglycosides and generation of a new mouse model
por: Brendel, Cornelia, et al.
Publicado: (2013) -
Balancing
Nonsense Mutation Readthrough and Toxicity
of Designer Aminoglycosides for Treatment of Genetic Diseases
por: Guchhait, Sandip, et al.
Publicado: (2023) -
Evaluation of Novel Enhancer Compounds in Gentamicin-Mediated Readthrough of Nonsense Mutations in Rett Syndrome
por: Wong, Keit Men, et al.
Publicado: (2023) -
Characterization of the MeCP2(R168X) Knockin Mouse Model for Rett Syndrome
por: Wegener, Eike, et al.
Publicado: (2014) -
Ex Vivo Treatment with a Novel Synthetic Aminoglycoside NB54 in Primary Fibroblasts from Rett Syndrome Patients Suppresses MECP2 Nonsense Mutations
por: Vecsler, Manuela, et al.
Publicado: (2011)